Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05306041
Title Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer (GeparPiPPa)
Acronym GeparPiPPa
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors German Breast Group
Age Groups: adult | senior
Covered Countries DEU

No variant requirements are available.